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Volume 60, Number 6 Abstracts 1711was used to estimate odds ratios for outcomes controlling for sex, race, dia-
betes, cardiovascular disease, smoking, and other confounders. There were
19,748 patients with CEA analyzed of whom 19,348 (97.97%) were func-
tionally independent. 377 (1.99%) were functionally partially dependent and
23 (0.12%) were functionally dependent. In the functionally independent
group there were 196 (1.01%) strokes, 84 (0.43%) deaths, and 1416
(17.17%) other complications. In the functionally partially dependent
group, there were 14 (3.71%) strokes, 10 (2.65%) deaths, and 80
(21.22%) other complications. In a multivariable risk-adjusted model using
functionally independent as a reference, functionally partially dependent was
associated with death (odds ratio, 3.3; 95% CI, 1.6-6.8; P < .001), stroke
(odds ratio, 3; 95% CI, 1.7-5.4; P < .001), and other complications
(odds ratio, 2.5; 95% CI, 1.9-3.2; P < .001).
Comment: The complication rates in the patients with inability to
perform activities of daily living fall outside guidelines from the Society of
Vascular Surgery and the American Heart Association. It appears that activ-
ities of daily living are a critical factor in predicting outcomes after CEA in
asymptomatic patients and, in combination with improved medical manage-
ment of asymptomatic carotid stenosis, suggests that in patients with high-
grade asymptomatic carotid stenosis, aggressive medical management may
be the best option for patients with impaired activities of daily living and
high-grade asymptomatic carotid stenosis. In patients considered for CEA
for asymptomatic lesions functional status should be vigilantly assessed as
an aid in risk stratiﬁcation along with other objective factors for potentially
identifying increased risk of adverse outcome after CEA.
Volume of Carotid Artery Ulceration as a Predictor of Cardiovascular
Events
Kuk M, Wannarong T, Beletsky V, et al. Stroke 2014;45:1437-41.
Conclusions: With three-dimensional ultrasound volume of carotid
ulceration accurately predicts cardiovascular events.
Summary: Ulcerated carotid plaques have been associated with plaque
rupture, intraplaque hemorrhage, and overall decreased plaque stability. In
addition, ulceration tends to be associated with greater plaque thickness
and plaque volume (Homburg PJ et al, Stroke 2011;42:367-72, and Riccio
SA et al, Cardiovasc Ultrasound 2006;4:44). There also appears to be
increased stroke risk with ulcerated plaques (Eliasziw M et al, Stroke
1994;25:304-8). Studies of plaque ulceration in the past have characterized
the atherosclerotic plaque as complex with (irregular morphology with ul-
cers) or smooth or by quantifying the number of ulcers observed in a region
of interest. In this study the aim was to quantify carotid total ulcer volume by
three-dimensional ultrasound to investigate the relationship of total ulcer vol-
ume to vascular events (stroke, transient ischemic attack, myocardial infarc-
tion, revascularization, or death because of cardiovascular reason). There
were 349 at-risk subjects who provided written informed consent for carotid
three-dimensional ultrasound and whose plaques were then analyzed for ul-
cerations. Ulcer volume was deﬁned as a distinct discontinuity in an athero-
sclerotic plaque, with a volume of $1.00 mm3 as measured using manual
segmentation. The sum of the volumes of all ulcers seen in both carotids
was the total ulcer volume. Participants were monitored for#5 years for out-
comes including cardiovascular events and death. Kaplan-Meier survival anal-
ysis demonstrated that subjects with total ulcer volume$5 mm3 experienced
signiﬁcantly higher risk of developing stroke, transient ischemic attack, or
death (P ¼ .009) and of developing stroke/transient ischemic attack/
death/myocardial infarction/revascularization (P ¼ .017). Lower ulcer vol-
umes did not predict events and ulcer depth did not predict events.
Comment: Intuitively it makes sense that at some level characteristics
of the carotid plaque ought to have something to do with its propensity to
induce neurologic events. The authors take this concept a bit further in that
they can have demonstrated that volume of ulceration can be measured withthree-dimensional ultrasound and that this variable correlates with risk for a
variety of cardiovascular events. The implication is that the atherosclerotic
process in some patients may have a tendency to produce more unstable pla-
ques conferring greater risk for cardiovascular events to the patient and that
this risk can somehow be assessed through the use of three-dimensional ul-
trasound of the carotid plaque.
Aspirin for the Prevention of Recurrent Venous Thromboembolism:
The INSPIRE Collaboration
Simes J, Becattini C, Agnelli G, et al. Circulation 2014;130:1062-71.
Conclusions: Aspirin after anticoagulation treatment for venous
thromboembolism (VTE) reduces overall risk of reoccurrence by more
than a third in a broad cross-section of patients with a ﬁrst unprovoked
VTE without signiﬁcantly increasing risk of bleeding.
Summary: Unprovoked VTE has a high risk of reoccurrence after
discontinuation of vitamin K antagonist therapy. The risk is approximately
10% within the ﬁrst year and 5% per year thereafter (Boutitie F et al, BMJ
2011;342:d3036). The new oral anticoagulants can lower the risk of recur-
rent VTE as part of initial or extended therapy. They are effective alterna-
tives to warfarin but also carry bleeding risk and are expensive. Aspirin is
a potential low-cost and relatively safe means of preventing further VTE
events in the patient with an unprovoked VTE initially treated with antico-
agulants. Aspirin has been recently evaluated in the Aspirin for the Preven-
tion of Recurrent Venous Thromboembolism Warfarin and Aspirin
(WARFASA) and the Aspirin to Prevent Recurrent Venous Thromboembo-
lism (ASPIRE) trials (Becattini C et al, N Engl J Med 2012;366:1959-67,
and Brighton TA et al, N Engl J Med 2012;367:1979-87). These trials
demonstrated aspirin reduced the risk of recurrent VTE but were not indi-
vidually powered to detect moderate treatment effects for particular out-
comes or subgroups. Combined patient-level analysis of WARFASA and
ASPIRE was planned, and a protocol for the project was developed before
publishing and unblinding of the results of either trial. The purpose of the
INSPIRE analysis was to more accurately estimate the effects of aspirin
treatment; overall, on individual outcomes and in prespeciﬁed subgroups
of patients. Individual patient data analysis of these trials was performed
to assess the effect of aspiring, vs placebo on recurrent VTE, major vascular
events (recurrent VTE, myocardial infarction, stroke, and cardiovascular dis-
ease death) and bleeding, overall and within predeﬁned subgroups. The pri-
mary analysis for VTE, was by intention to treat using the time-to-event
data of 1224 patients, 193 had recurrent VTE over 30.4 months median
follow-up. Aspirin reduced recurrent VTE (7.5%/yr vs 5.1%/yr; hazard ra-
tio [HR], 0.68; 95% conﬁdence interval [CI], 0.51-0.90; P ¼ .008),
including both deep-vein thrombosis (HR, 0.66; 95% CI, 0.47-0.92; P ¼
.01) and pulmonary embolism (HR, 0.66; 95% CI, 0.41-1.06; P¼.08).
Aspirin reduced major vascular events (8.7%/yr vs 5.7%/yr; HR 0.66;
95% CI, 0.50-0.86; P ¼ .002). The major bleeding rate was low (0.4%/
yr for placebo and 0.5%/yr for aspirin). After adjustment for treatment
adherence, recurrent VTE was reduced by 42% (HR, 0.58; 95% CI, 0.40-
0.85; P ¼ .005). Prespeciﬁed subgroup analyses indicate similar relative,
but larger absolute, risk reductions in men and older patients.
Comment: While extended anticoagulation therapy is still the most
effective means of preventing recurrent VTE following unprovoked VTE,
such therapy is impractical and undesirable for most patients with initial
VTE events. The data here show that aspirin is a cheap, safe alternative to
reducing VTE risk following an initial period of anticoagulation for an
unprovoked initial VTE event. As such, it seems there is no reason to leave
patients completely unprotected for recurrent VTE events following an
initial period of anticoagulation. Aspirin reduces the risk of another VTE
event and is a safe treatment for these patients. Additional data will be
needed to know how long to continue aspirin in such patients and whether
the safety proﬁle continues over a longer periods of time.
